Literature DB >> 26763969

Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?

Niaz Banaei1, Rajiv L Gaur2, Madhukar Pai3.   

Abstract

Interferon gamma release assays (IGRAs) are blood-based tests intended for diagnosis of latent tuberculosis infection (LTBI). IGRAs offer logistical advantages and are supposed to offer improved specificity over the tuberculin skin test (TST). However, recent serial testing studies of low-risk individuals have revealed higher false conversion rates with IGRAs than with TST. Reproducibility studies have identified various sources of variability that contribute to nonreproducible results. Sources of variability can be broadly classified as preanalytical, analytical, postanalytical, manufacturing, and immunological. In this minireview, we summarize known sources of variability and their impact on IGRA results. We also provide recommendations on how to minimize sources of IGRA variability.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26763969      PMCID: PMC4809912          DOI: 10.1128/JCM.02803-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing.

Authors:  A Naseer; S Naqvi; B Kampmann
Journal:  Eur Respir J       Date:  2007-06       Impact factor: 16.671

2.  Booster phenomenon of QuantiFERON-TB Gold after prior intradermal PPD injection.

Authors:  H Igari; A Watanabe; T Sato
Journal:  Int J Tuberc Lung Dis       Date:  2007-07       Impact factor: 2.373

3.  Reproducibility of QuantiFERON-TB gold in-tube assay.

Authors:  Sharon Perry; Luz Sanchez; Shufang Yang; Zubin Agarwal; Philip Hurst; Julie Parsonnet
Journal:  Clin Vaccine Immunol       Date:  2008-01-16

Review 4.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

5.  Defective antigen tubes generate false-positive QuantiFERON tuberculosis test results.

Authors:  Marc Roger Couturier; Robbie Myatt; Don Dorn; David T Yang; Nancy Pitstick
Journal:  Clin Infect Dis       Date:  2014-08-08       Impact factor: 9.079

Review 6.  Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.

Authors:  Saloua Tagmouti; Madeline Slater; Andrea Benedetti; Sandra V Kik; Niaz Banaei; Adithya Cattamanchi; John Metcalfe; David Dowdy; Richard van Zyl Smit; Nandini Dendukuri; Madhukar Pai; Claudia Denkinger
Journal:  Ann Am Thorac Soc       Date:  2014-10

7.  T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals.

Authors:  Thomas C King; Mark Upfal; Andrew Gottlieb; Philip Adamo; Edward Bernacki; Chris P Kadlecek; Jeffrey G Jones; Frances Humphrey-Carothers; Albert F Rielly; Pamela Drewry; Kathy Murray; Marcie DeWitt; Janet Matsubara; Louis O'Dea; John Balser; Peter Wrighton-Smith
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

8.  Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing.

Authors:  Richard N van Zyl-Smit; Madhukar Pai; Kwaku Peprah; Richard Meldau; Jackie Kieck; June Juritz; Motasim Badri; Alimuddin Zumla; Leonardo A Sechi; Eric D Bateman; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2009-04-02       Impact factor: 21.405

9.  Serial testing of refugees for latent tuberculosis using the QuantiFERON-gold in-tube: effects of an antecedent tuberculin skin test.

Authors:  Cristina A Baker; William Thomas; William M Stauffer; Phillip K Peterson; Dean T Tsukayama
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

10.  Indeterminate test results of T-SPOT.TB performed under routine field conditions.

Authors:  P Beffa; A Zellweger; J-P Janssens; P Wrighton-Smith; J-P Zellweger
Journal:  Eur Respir J       Date:  2007-12-05       Impact factor: 16.671

View more
  29 in total

1.  Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Authors:  Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill
Journal:  Lancet Respir Med       Date:  2017-02-16       Impact factor: 30.700

2.  Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Authors:  Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

3.  Higher Positivity Rate with Fourth-Generation QuantiFERON-TB Gold Plus Assay in Low-Risk U.S. Health Care Workers.

Authors:  Catherine A Hogan; Sara Tien; Madhukar Pai; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

Review 4.  Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?

Authors:  Arena Shafeque; Jacob Bigio; Catherine A Hogan; Madhukar Pai; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

5.  Performance of the QuantiFERON®-TB Gold In-Tube assay in tuberculin skin test converters: a prospective cohort study.

Authors:  M E Castellanos; S Kirimunda; L Martinez; T Quach; H Woldu; R Kakaire; A Handel; S Zalwango; N Kiwanuka; C C Whalen
Journal:  Int J Tuberc Lung Dis       Date:  2018-09-01       Impact factor: 2.373

6.  Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers.

Authors:  Oh Joo Kweon; Yong Kwan Lim; Hye Ryoun Kim; Tae-Hyoung Kim; Mi-Kyung Lee
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

7.  Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients.

Authors:  Mi Ra Ryu; Min-Seung Park; Eun Hye Cho; Chul Won Jung; Kihyun Kim; Seok Jin Kim; Ha Young Oh; Wooseong Huh; Hye Ryoun Jang; Won-Jung Koh; Hye Yun Park; Young-Ho Kim; Dong Hyun Sinn; Jin-Oh Choi; Jae-Won Joh; Jong Man Kim; Sung Joo Kim; Jae Berm Park; Eun-Suk Kang
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

8.  Risk of latent and active tuberculosis infection in travellers: a systematic review and meta-analysis.

Authors:  Tanya R Diefenbach-Elstob; Balqis Alabdulkarim; Paromita Deb-Rinker; Jeffrey M Pernica; Guido Schwarzer; Dick Menzies; Ian Shrier; Kevin Schwartzman; Christina Greenaway
Journal:  J Travel Med       Date:  2021-01-06       Impact factor: 8.490

9.  Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting.

Authors:  Hee-Won Moon; Rajiv L Gaur; Sara Shu-Hwa Tien; Mary Spangler; Madhukar Pai; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2017-03-15       Impact factor: 5.948

10.  Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Authors:  Elitza S Theel; Heather Hilgart; Margaret Breen-Lyles; Kevin McCoy; Rhiannon Flury; Laura E Breeher; John Wilson; Irene G Sia; Jennifer A Whitaker; Jeremy Clain; Timothy R Aksamit; Patricio Escalante
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.